Rheumajecta in the treatment of rheumatoid arthritis.
A double-blind controlled trial of Rheumajecta in rheumatoid arthritis demonstrated lack of effect of this compound and unacceptable side-effects. It was not felt ethically justifiable to complete the trial.
D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002374:Catalase / Q000627:therapeutic use*; D002795:Choline O-Acetyltransferase / Q000627:therapeutic use*; D004338:Drug Combinations / Q000627:therapeutic use; D004341:Drug Evaluation; D006801:Humans; D009713:Nucleotidyltransferases / Q000627:therapeutic use*; D013430:Sulfate Adenylyltransferase / Q000627:therapeutic use*; D013466:Sulfurtransferases / Q000627:therapeutic use*
D000893:Anti-Inflammatory Agents; D004338:Drug Combinations; C023681:Rheumajecta; D002374:Catalase; D002795:Choline O-Acetyltransferase; D009713:Nucleotidyltransferases; D013430:Sulfate Adenylyltransferase; D013466:Sulfurtransferases